• ALDH1A3-miR-7-TGFBR2 Axis Regulates CD44 in Breast CSCs

  2026-04-20

  This study reveals that ALDH1A3 knockdown reduces the breast cancer stem cell (BCSC) marker CD44 via a miR-7–TGFBR2–Smad3–CD44 regulatory axis. The findings highlight a mechanistic link between ALDH1A3, microRNA expression, TGF-β signaling, and stemness, with implications for targeted breast cancer therapy.

• Applied Workflows with ARCA Cy3 EGFP mRNA (5-moUTP): Imaging

  2026-04-20

  ARCA Cy3 EGFP mRNA (5-moUTP) redefines mRNA delivery and imaging with direct fluorescence tracking and robust EGFP expression in mammalian systems. This guide details actionable protocols, troubleshooting tips, and evidence-based optimizations enabled by its unique 5-methoxyuridine and Cy3 modifications.

• Cy3 Goat Anti-Rabbit IgG (H+L) Antibody: Protocol and QC Gui

  2026-04-19

  The Cy3 Goat Anti-Rabbit IgG (H+L) Antibody addresses sensitivity and specificity challenges in detecting rabbit primary antibodies across immunofluorescence, IHC, and related workflows. It delivers reproducible signal amplification, but its application is limited to research use and compatible detection platforms where Cy3 fluorescence is suitable.

• TaqI Restriction Endonuclease: Fast, Reliable DNA Digestion

  2026-04-18

  TaqI Restriction Endonuclease (SKU K3053) offers rapid and precise DNA cleavage for plasmid, PCR, and genomic DNA workflows, enabling efficient sticky-end generation in molecular biology labs. It is appropriate for research applications requiring quick, reproducible digestion, but should not be used in diagnostic or medical contexts.

• IGF2BP1-m6A-THBS1 Axis Drives Macrophage Fibrosis in the Lun

  2026-04-17

  This study reveals how the m6A reader IGF2BP1 stabilizes THBS1 mRNA, promoting macrophage glycolytic metabolism and M2 polarization, which contribute to pulmonary fibrosis. The work defines a new IGF2BP1/THBS1/TLR4 regulatory axis, offering mechanistic insights and potential intervention points for fibrotic lung disease.

• PP 1 in Precision Oncology: Src Kinase Inhibition in Resista

  2026-04-16

  Explore how PP 1, a potent Src family tyrosine kinase inhibitor, enables advanced dissection of resistance mechanisms in HER2+ breast cancer and beyond. This article delivers deep scientific analysis and practical guidance that extends beyond existing coverage.

• Perphenazine in Translational Research: Mechanism and Strate

  2026-04-15

  Explore how Perphenazine, a dopamine D2 receptor antagonist, bridges neuropharmacology and host-pathogen research. This thought-leadership article offers mechanistic insights, protocol guidance, and strategic vision for translational researchers leveraging APExBIO’s Perphenazine across advanced experimental workflows.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-04-14

  Schwartz (2022) advances how anti-cancer drug responses are evaluated in vitro by rigorously distinguishing between cell growth inhibition and cell death metrics. This work enables more nuanced assessment of compounds like Artesunate, enhancing translational relevance for cancer therapy research.

• Crizotinib Hydrochloride in ALK Kinase Inhibitor Workflows

  2026-04-13

  Crizotinib hydrochloride empowers cancer biology research by enabling precise inhibition of ALK and c-Met phosphorylation in physiologically relevant assembloid models. Its robust solubility and assay versatility help researchers dissect oncogenic signaling and resistance mechanisms within complex tumor microenvironments.

• Applied Dextrose (D-glucose) Workflows for Immunometabolic R

  2026-04-12

  Dextrose (D-glucose) unlocks reproducible, high-impact results in glucose metabolism and immunometabolic research, especially in hypoxic tumor settings. This article delivers actionable workflows, troubleshooting strategies, and protocol parameters—translating cutting-edge literature into bench-ready guidance.

• Applied Workflows with ARCA Cy3 EGFP mRNA (5-moUTP) in Cell

  2026-04-12

  ARCA Cy3 EGFP mRNA (5-moUTP) delivers direct, quantitative visualization of mRNA uptake and translation in mammalian cells, outperforming traditional controls for transfection optimization and innate immune evasion. Its 5-methoxyuridine modification, ARCA capping, and Cy3 labeling converge to streamline live-cell imaging and precise localization studies.

• Applied Use of IWP-2: Wnt Production Inhibitor in Cancer Res

  2026-04-11

  IWP-2, a potent Wnt production inhibitor from APExBIO, offers precision targeting of the Wnt/β-catenin pathway in preclinical cancer and cell signaling research. This article details optimized workflows, protocol refinements, and troubleshooting strategies to maximize experimental reliability when using IWP-2.

• 10074-G5: c-Myc Inhibitor Workflows for Advanced Cancer Rese

  2026-04-11

  10074-G5 empowers researchers to precisely disrupt c-Myc-driven oncogenic pathways, enabling robust apoptosis and tumor regression studies. This guide delivers hands-on protocols, troubleshooting strategies, and workflow enhancements for translational cancer research leveraging APExBIO’s 10074-G5.

• Hexetidine (NSC-17764): Advancing Oral Antimicrobial Scie...

  2026-04-10

  This thought-leadership article explores Hexetidine (NSC-17764) as a broad-spectrum antimicrobial agent, bridging molecular insights with translational strategies for oral infection research. It provides a mechanistic deep dive, rigorous experimental validation, and critical analysis of the competitive antiseptic landscape. With strategic guidance for translational researchers, the article highlights Hexetidine’s distinctive membrane-disruptive mechanism, optimal assay use, clinical positioning, and future innovation beyond conventional product summaries.

• Hexetidine (NSC-17764): Redefining Oral Antimicrobial Str...

  2026-04-09

  Hexetidine (NSC-17764) stands at the forefront of broad-spectrum oral antimicrobial innovation, offering unique mechanistic, experimental, and translational advantages over conventional antiseptics. This thought-leadership article bridges fundamental insights into microbial membrane disruption and metabolism interference with actionable strategies for researchers and clinicians. By integrating recent evidence—including surface adsorption effects, biofilm model optimization, and synergistic co-therapies—this piece delivers a data-driven roadmap for maximizing efficacy in oral infection research and clinical practice. With contextual references to foundational studies and the latest workflow guidance, it demonstrates how Hexetidine, available from APExBIO, empowers the next generation of oral health solutions.

452 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page